ACE2 (extracellular) Blocking Peptide (#BLP-AC012) is the original antigen used for immunization during Anti-ACE2 (extracellular) Antibody (#AAC-012) generation. The blocking peptide binds and ‘blocks’ Anti-ACE2 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat small intestine lysate (lanes 1 and 4), mouse lung lysate (lanes 2 and 5 ) and mouse kidney lysate (lanes 3 and 6):
- Western blot analysis of human HepG2 hepatoma cell line lysate (lanes 1 and 3) and human THP-1 monocytic leukemia cell line lysate (lanes 2 and 4):
- Expression of ACE2 in mouse thalamus.Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-ACE2 (extracellular) Antibody (#AAC-012), (1:200), followed by goat anti-rabbit-AlexaFluor-488. A. ACE2 immunoreactivity (green) appears in neurons (arrows). B. Pre-incubation of the antibody with ACE2 (extracellular) Blocking Peptide (BLP-AC012), suppressed staining. Cell nuclei are stained with DAPI (blue).
- Peptide (C)EDYGDYWRGDYEVNGVD, corresponding to amino acid residues 197 - 213 of human ACE2 (Accession Q9BYF1).